Verona Pharma submits FDA New Drug Application for COPD treatment
James Spargo | June 27, 2023 | News story | Research and Development | COPD, Cardiology, FDA, ensifentrine, new drug application, verona pharma
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its chronic obstructive pulmonary disease (COPD) maintenance drug, ensifentrine.
Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The high dual sensitivity of PDE3 and PDE4 over other enzymes and receptors minimises off-target effects, while direct delivery to the lungs via inhalation maximises pulmonary exposure while lessening systemic distribution.
More than 2,200 patients have been dosed with the drug through phase 1-3 ENHANCE clinical trials, with ensifentrine being well-tolerated throughout. The drug met its primary endpoints in ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. It also reduced the rare and risk of COPD exacerbations in analysis.
David Zaccardelli PharmD, president and CEO of Verona Pharma, stated: “Millions of symptomatic COPD patients in the US are in urgent need of new treatment options. The NDA submission for ensifentrine is a significant milestone towards our goal of bringing this potential first-in-class therapy to COPD patients and we look forward to working with the FDA during their review.”
James Spargo
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
